Drug intelligence / Profile preview

Dfriz

Development stage: Unknown
Lead developer: Sinsan Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Dfriz** is an oral fixed-dose combination tablet marketed by Sinsan Pharmaceuticals for **osteoarthritis**. It contains diacerein 50 mg, glucosamine 750 mg, and methylsulfonylmethane 250 mg. Diacerein is a symptomatic slow-acting osteoarthritis drug whose active metabolite rhein is associated with suppression of interleukin-1-mediated inflammatory and cartilage-degrading processes; glucosamine supports proteoglycan and cartilage-matrix synthesis; and methylsulfonylmethane is included for supportive anti-inflammatory and joint-symptom management. ([1mg.com](https://www.1mg.com/drugs/dfriz-750mg-50mg-250mg-tablet-427325))

Brand names: Dfriz
Other names: diacerein + glucosamine + methylsulfonylmethane

Beyond the preview

Go deeper on Dfriz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dfriz.

Explore the full profile